Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
COMMENTARY Don't Write Us Oldies Off!
January 15, 2001
-
ARCHIVE SBS Transfers Tagamet to Sumitomo
January 15, 2001
-
ARCHIVE BUSINESS NEWS IN BRIEF -1-
January 15, 2001
-
COMMENTARY Changing Japanese Heathcare Scene - Health Care Transition Leads Evaluation of Pharma Market -
January 15, 2001
-
ARCHIVE SmithKline Beecham: Hycamtin Approved for Small Cell Lung Cancer
January 15, 2001
-
ARCHIVE BUSINESS NEWS IN BRIEF -2-
January 15, 2001
-
ARCHIVE New Health Ministry's Budget Totals \18 Trillion, +4.5% Over FY2000
January 15, 2001
-
ARCHIVE Fukujin Becomes Hokuho Iyaku's Major Shareholder
January 15, 2001
-
ARCHIVE Banyu Confirms Efficacy, Safety of Simvastatin in Clinical Trail
January 15, 2001
-
ARCHIVE Arimidex Approved as 1st Drug Based on Bridging Studies in Japan
January 15, 2001
-
ARCHIVE Dainippon Starts Full Operation of New PMS Information System
January 15, 2001
-
ARCHIVE medical facilities & nursing care news on brief
January 15, 2001
-
ARCHIVE Use of Overseas Data Recommended to Develop Pediatric Drugs
January 15, 2001
-
ARCHIVE Use New Technology to Meet Existing Needs in Healthcare: Mr Tanimura
January 15, 2001
-
ARCHIVE Cooperation with Companies Is Essential: RIKEN Researcher
January 15, 2001
-
ARCHIVE CPAC to Become Pharmaceutical Affairs and Food Sanitation Council
January 15, 2001
-
ARCHIVE Tissue Engineering Chair Donated by BCS at Tokai Univ.
January 15, 2001
-
ARCHIVE CAPC's Executive Committee Recommends Approval of 16 Active Ingredients
January 15, 2001
-
ARCHIVE abbreviation
January 15, 2001
-
ARCHIVE REGULATORY NEWS IN BRIEF -2-
January 15, 2001
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…